Advanced in Cortical Dysplasia

Dr. David H. Viskochil

Medical Genetics
Intermountain Health
University Of Utah Pediatric Genetic & Metabolism Clinic
81 North Mario Capecchi Drive, 
Salt Lake City, UT 
Accepting New Patients
Offers Telehealth
41 Years of Experience
Advanced in Cortical Dysplasia
Intermountain Health
University Of Utah Pediatric Genetic & Metabolism Clinic
81 North Mario Capecchi Drive, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Viskochil is a Medical Genetics provider in Salt Lake City, Utah. Dr. Viskochil has been practicing medicine for over 41 years and is rated as an Advanced provider by MediFind in the treatment of Cortical Dysplasia. His top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, and Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome). Dr. Viskochil is currently accepting new patients.

His clinical research consists of co-authoring 97 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 6 articles in the study of Cortical Dysplasia.

Graduate Institution
University Of North Carolina At Chapel Hill, 1985
Residency
University of Utah
Specialties
Medical Genetics
Licenses
Clinical Genetics in UT
Board Certifications
American Board Of Medical Genetics & Genomics
Fellowships
University of Utah
Hospital Affiliations
Primary Children's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

University of Utah Pediatric Genetic & Metabolism Clinic
81 North Mario Capecchi Drive, Salt Lake City, UT 84113
Call: 801-213-3599
Other Locations
Primary Children's Hospital - Genetics & Metabolic Clinic
81 North Mario Capecchi Drive, Salt Lake City, UT 84113
Call: 801-213-3599

Additional Areas of Focus

Dr. Viskochil has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Enrollment Status: Active_not_recruiting
Publish Date: October 22, 2025
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug
Study Drug: Binimetinib
Study Phase: Phase 2
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Extended-Release Tablets in Participants With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
Enrollment Status: Completed
Publish Date: April 19, 2024
Intervention Type: Drug
Study Drug: DCCR (diazoxide choline controlled release tablets)
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Enrollment Status: Terminated
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drug: RAD011
Study Phase: Phase 2/Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drug: AGT-181
Study Phase: Phase 1
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)
Enrollment Status: Completed
Publish Date: July 26, 2022
Intervention Type: Drug
Study Drug: Intranasal carbetocin
Study Phase: Phase 3
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

97 Total Publications

RNA sequencing provides functional insights and diagnostic resolution in previously unsolved rare disease cases.
RNA sequencing provides functional insights and diagnostic resolution in previously unsolved rare disease cases.
Journal: BMC medical genomics
Published: June 25, 2025
View All 97 Publications
Similar Doctors
Advanced in Cortical Dysplasia
Dr. Lorenzo D. Botto
Medical Genetics | Pediatrics
Advanced in Cortical Dysplasia
Dr. Lorenzo D. Botto
Medical Genetics | Pediatrics

University Of Utah Pediatric Services

81 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-213-3599
Languages Spoken:
English, Italian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lorenzo Botto is a Medical Genetics specialist and a Pediatrics provider in Salt Lake City, Utah. Dr. Botto is rated as an Advanced provider by MediFind in the treatment of Cortical Dysplasia. His top areas of expertise are Gastroschisis, Omphalocele, Increased Head Circumference, and Schwartz-Jampel Syndrome. Dr. Botto is currently accepting new patients.

Experienced in Cortical Dysplasia
Dr. Brian J. Shayota
Pediatrics | Medical Genetics
Experienced in Cortical Dysplasia
Dr. Brian J. Shayota
Pediatrics | Medical Genetics

University Of Utah Pediatric Services

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-587-7109
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Shayota is a Pediatrics specialist and a Medical Genetics provider in Salt Lake City, Utah. Dr. Shayota is rated as an Advanced provider by MediFind in the treatment of Cortical Dysplasia. His top areas of expertise are Hartnup Disease, Robinow Syndrome, Genital Dwarfism, and Smith-Magenis Syndrome. Dr. Shayota is currently accepting new patients.

VIEW MORE CORTICAL DYSPLASIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Viskochil's expertise for a condition
ConditionClose
  • Elite
  • Neurofibromatosis
    Dr. Viskochil is
    Elite
    . Learn about Neurofibromatosis.
    See more Neurofibromatosis experts
  • Neurofibromatosis Type 1 (NF1)
    Dr. Viskochil is
    Elite
    . Learn about Neurofibromatosis Type 1 (NF1).
    See more Neurofibromatosis Type 1 (NF1) experts
  • Distinguished
  • Legius Syndrome
    Dr. Viskochil is
    Distinguished
    . Learn about Legius Syndrome.
    See more Legius Syndrome experts
  • Malignant Peripheral Nerve Sheath Tumor
    Dr. Viskochil is
    Distinguished
    . Learn about Malignant Peripheral Nerve Sheath Tumor.
    See more Malignant Peripheral Nerve Sheath Tumor experts
  • Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome)
    Dr. Viskochil is
    Distinguished
    . Learn about Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome).
    See more Mucopolysaccharidosis Type 1 (MPS I, Hurler Syndrome) experts
  • Prader-Willi Syndrome
    Dr. Viskochil is
    Distinguished
    . Learn about Prader-Willi Syndrome.
    See more Prader-Willi Syndrome experts
  • Advanced
  • Aplasia Cutis Congenita
    Dr. Viskochil is
    Advanced
    . Learn about Aplasia Cutis Congenita.
    See more Aplasia Cutis Congenita experts
  • Cardiofaciocutaneous Syndrome
    Dr. Viskochil is
    Advanced
    . Learn about Cardiofaciocutaneous Syndrome.
    See more Cardiofaciocutaneous Syndrome experts
  • Clouston Syndrome
    Dr. Viskochil is
    Advanced
    . Learn about Clouston Syndrome.
    See more Clouston Syndrome experts
  • Cortical Dysplasia
    Dr. Viskochil is
    Advanced
    . Learn about Cortical Dysplasia.
    See more Cortical Dysplasia experts
  • Costello Syndrome
    Dr. Viskochil is
    Advanced
    . Learn about Costello Syndrome.
    See more Costello Syndrome experts
  • Ectodermal Dysplasias
    Dr. Viskochil is
    Advanced
    . Learn about Ectodermal Dysplasias.
    See more Ectodermal Dysplasias experts
View All 9 Advanced Conditions
  • Experienced
  • Achalasia Microcephaly Syndrome
    Dr. Viskochil is
    Experienced
    . Learn about Achalasia Microcephaly Syndrome.
    See more Achalasia Microcephaly Syndrome experts
  • Brachydactyly Mononen Type
    Dr. Viskochil is
    Experienced
    . Learn about Brachydactyly Mononen Type.
    See more Brachydactyly Mononen Type experts
  • CHARGE Syndrome
    Dr. Viskochil is
    Experienced
    . Learn about CHARGE Syndrome.
    See more CHARGE Syndrome experts
  • Classical Hodgkin Lymphoma
    Dr. Viskochil is
    Experienced
    . Learn about Classical Hodgkin Lymphoma.
    See more Classical Hodgkin Lymphoma experts
  • Dandy-Walker Syndrome
    Dr. Viskochil is
    Experienced
    . Learn about Dandy-Walker Syndrome.
    See more Dandy-Walker Syndrome experts
  • Holoprosencephaly
    Dr. Viskochil is
    Experienced
    . Learn about Holoprosencephaly.
    See more Holoprosencephaly experts
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.